IQVIA Holdings Inc.

NYSE IQV

IQVIA Holdings Inc. Dividend Yield on January 14, 2025: 0.00%

IQVIA Holdings Inc. Dividend Yield is 0.00% on January 14, 2025, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
  • IQVIA Holdings Inc. 52-week high Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
  • IQVIA Holdings Inc. 52-week low Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
  • IQVIA Holdings Inc. average Dividend Yield for the last 52 weeks is 0.00%.
Key data
Date Dividend Yield Free Cash Flow Yield Earnings Yield Enterprise Value (EV)
Market news
Loading...
NYSE: IQV

IQVIA Holdings Inc.

CEO Mr. Ari Bousbib
IPO Date May 9, 2013
Location United States
Headquarters 4820 Emperor boulevard
Employees 88,000
Sector Health Care
Industries
Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Similar companies

QGEN

Qiagen N.V.

USD 45.57

-0.94%

MEDP

Medpace Holdings, Inc.

USD 330.91

-5.99%

ICLR

ICON Public Limited Company

USD 200.24

-8.14%

IDXX

IDEXX Laboratories, Inc.

USD 418.63

-0.94%

NEOG

Neogen Corporation

USD 12.00

-5.06%

RVTY

Revvity, Inc.

USD 120.73

-1.61%

LH

Laboratory Corporation of America Holdings

USD 234.50

0.17%

WAT

Waters Corporation

USD 404.93

1.26%

CRL

Charles River Laboratories International, Inc.

USD 178.08

-6.34%

TWST

Twist Bioscience Corporation

USD 42.75

-1.91%

MTD

Mettler-Toledo International Inc.

USD 1.27 K

0.33%

StockViz Staff

January 15, 2025

Any question? Send us an email